Senseonics Holdings Sees $100 Million-Plus in 2027 Sales, Eyes New Eversense Launches

Key Points

• Senseonics’ executives said they are comfortable with more than $100 million in 2027 sales and expect gross margin above 60%. They also anticipate lower cash burn as revenue grows, after using about $120 million in cash during 2026.
• The company expects to launch its Gemini sensor in the second half of 2027 and is targeting Freedom, designed for pump integration, around the second quarter of 2028. Freedom is expected to have gross margin above 70% and could help drive cash-flow breakeven.
• Bringing commercial operations in-house has reduced complexity, while advertising and broader prescriber reach have supported Eversense growth. Senseonics is expanding its nurse insertion network and pursuing pump integrations, including an imminent launch with Beta Bionics’ iLet.

Senseonics Holdings, Inc. Common Stock NASDAQ: SENS executives said the company’s return of commercial operations in-house has improved efficiency and supported growth in its Eversense diabetes monitoring business, while outlining plans for new products and insulin pump partnerships.

Speaking at a Stifel event following the company’s third-quarter report, CEO Timothy Goodnow said investments in awareness beginning in late 2025 helped drive performance through the first three quarters of 2026. Stifel’s Jon Block said revenue and gross margin exceeded expectations and that Senseonics raised guidance for the third time this year.

The company transferred commercial responsibilities from partner Ascensia Diabetes Care. Chief Commercial Officer Brian Hansen said bringing the functions together reduced complexity, including the need to coordinate forecasts and contracts between the two companies.

Goodnow said the transition in Europe took longer, partly because CE marking for the Eversense 365 product lagged its U.S. approval. Hansen said the European commercial team is now in place and should become more productive as it enters 2027.

Marketing and financial outlook

CFO Rick Sullivan said Senseonics spent approximately $13 million to $14 million on direct-to-consumer advertising in the second half of 2025 and allocated a similar amount more evenly across 2026. He said the company has seen improved efficiency in generating workable leads and intends to continue investing in the channel in 2027.

Goodnow estimated that more than 5,000 individual physicians prescribe Eversense 365 in the United States. Hansen said growth is coming from both greater use at existing accounts and new prescribers reached through advertising, particularly primary care physicians treating people with type 2 diabetes.

Sullivan said international sales are expected to account for about 15% of revenue this year, down from an initial expectation of 20% as U.S. growth has been strong. He expects the international share to remain around that level or decline slightly as Europe begins its 365-day product rollout.

Senseonics expects to use approximately $120 million in cash during 2026, Sullivan said. It ended the quarter with $127 million in cash and had $85 million of additional capacity under its Hercules facility. Sullivan expects cash burn to decline in 2027 as revenue grows and operating leverage improves.

Sullivan reiterated that he was comfortable with more than $100 million in 2027 sales and said he expects a gross margin above 60% next year. Discussing an illustrative $60 million quarterly revenue figure for late 2028, he said it was not “a scary number,” while noting that the scenario depends on the planned Freedom product. The executives did not present the figure as formal guidance.

Product pipeline and pump integrations

Goodnow said Senseonics is targeting the second half of 2027 for Gemini, a version of its sensor designed to use an implanted battery without a transmitter on the skin. The company pushed back Gemini’s development and submission timeline to prioritize starting a first-in-human clinical trial for Freedom, he said.

Freedom is intended to add internal Bluetooth connectivity and support pump integration. Goodnow said the company is working toward a launch around the second quarter of 2028, plus or minus a quarter. Sullivan said Senseonics expects Freedom to carry a gross margin above 70% and views it as a catalyst for reaching cash-flow breakeven.

On pump partnerships, Hansen said integration with Beta Bionics’ iLet was expected to launch in the next week or two. He said Senseonics also hopes to integrate with Beta Bionics’ planned mint patch pump when that product launches in 2027. Senseonics already works with Sequel’s twiist pump.

Insertion network expansion

Goodnow said patients with type 2 diabetes account for approximately 80% to 85% of current starts. For prescribers who do not perform insertions, Senseonics uses its EON network of independent nurses to facilitate the procedure.

The company expects to expand the network to 120 nurses by year-end and plans further growth next year, although it has not set a target. Goodnow confirmed that EON handled 40% of insertions in the third quarter.

About Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS)

Senseonics Holdings, Inc. is a medical technology company focused on developing and commercializing long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes. Its CGM technology is designed to measure glucose levels continuously through a small sensor inserted under the skin, with readings transmitted to an external smart transmitter and mobile application. The company's primary product is the Eversense CGM system. Unlike many conventional CGM systems that use an externally worn sensor, Eversense uses an implantable sensor and a removable, rechargeable transmitter worn over the sensor site.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.